Roche Signs Agreement to Acquire Memory Pharmaceuticals (MEMY) For $50 Million
More News related to MEMY
- Roche (RHHBY) Purchases Shares of Memory Pharmaceuticals (MEMY) in Tender Offer
- Notable Mergers and Acquisitions of the Day 11/25: BHP/RTP, MEMY
- Roche Signs Agreement to Acquire Memory Pharmaceuticals (MEMY) For $50 Million
- Memory Pharmaceuticals (MEMY) Achieves Enrollment Goal for Phase 2 Trial of MEM 3454
- Memory Pharmaceuticals (MEMY) Announces 55% Reduction in Workforce; Appoints Smith as CFO
More News related to Corporate News
- New Jersey AG Approves Limited Use of Electronic Stun Guns (TASR)
- Salix Pharma (SLXP) Completes 5.5M Common Offering at $21/Share
- Highlights From LDK's Q3 Conference Call: Sales up 23% Over Prior Quarter; Guides Well Above for Q4
- Highlights From JOBS Q3 Conference Call: Shares Jump on Strong Earnings and Rebound in Market Demand
- Empire Resorts (NYNY) Confirms St. Regis Mohawk Tribe Voted Against Pursing Off-Reservation Gaming in Catskills
Roche and Memory Pharmaceuticals (Nasdaq: MEMY) announced that the two companies have signed a definitive merger agreement for Roche to acquire all the outstanding shares of Memory Pharmaceuticals in an all-cash transaction for an aggregate price of approximately USD 50 million.
Memory Pharmaceuticals develops innovative drug candidates for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. Memory Pharmaceuticals' nicotinic alpha-7 agonist drug candidates in these disease areas are already in partnered programmes with Roche: R3487/MEM 3454 is in phase II clinical trials for Alzheimer's disease and schizophrenia; R4996/MEM 63908 is in phase I for Alzheimer's disease.
Related Categories
Corporate NewsMergers and Acquisitions
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
